The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts

Assessment of receptor contribution

Cecile Rouleau, Krishna Menon, Paula Boutin, Cheryl Guyre, Hitoshi Yoshida, Shiro Kataoka, Michael Perricone, Srinivas Shankara, Arthur E. Frankel, Nicholas S. Duesbery, George Vande Woude, Hans Peter Biemann, Beverly A. Teicher

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Two of the three components of anthrax toxin, protective antigen (PA) and lethal factor (LF), together known as lethal toxin (LeTx), reportedly show anti-tumor activity in melanoma in vitro and in vivo. The growth inhibitory activity of LeTx in culture was determined in nine human cancer cell lines, including melanoma, neuroblastoma and adenocarcinoma cells, as well as in human umbilical vein endothelial cells (HUVEC). The contribution of the two known PA receptor proteins, ANTXR1/TEM8 and ANTXR2/CMG2, to the sensitivity of the cells was assessed. The efficacy of LeTx was evaluated in vivo in the SK-N-AS neuroblastoma and SK-MEL-28 melanoma tumor xenograft models. Sensitivity to LeTx in vitro was observed in the neuroblastoma and colorectal adenocarcinoma cells and HUVEC, as well as melanoma cells. ANTXR1/TEM8 and ANTXR2/CMG2 protein expression studies suggested that a certain threshold of the PA receptor protein level must be met for sensitivity to LeTx to be observed. However, although the SK-N-AS neuroblastoma cells expressed the highest levels of receptor proteins and achieved the lowest IC50 in vitro (0.1 ng/ml), we observed no correlation between either the ANTXR1/TEM8 or ANTXR2/CMG2 protein levels and sensitivity to LeTx in vitro, In vivo, LeTx was an active anti-tumor agent when administered intravenously to mice bearing the human SK-N-AS or SK-MEL-28 tumor xenografts. The tumor growth delays were 6-8 days with a lower dose regimen and 14-16 days with a higher dose regimen for the two tumor models. These in vitro data suggest that LeTx may have broad therapeutic indications in cancer and the in vivo studies demonstrate that LeTx has systemic efficacy in neuroblastoma as well as melanoma. The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein.

Original languageEnglish (US)
Pages (from-to)739-748
Number of pages10
JournalInternational Journal of Oncology
Volume32
Issue number4
StatePublished - Apr 2008

Fingerprint

Neuroblastoma
Heterografts
Melanoma
Growth
Neoplasms
Antigen Receptors
Proteins
Human Umbilical Vein Endothelial Cells
Adenocarcinoma
Inhibitory Concentration 50
In Vitro Techniques
Cell Line
Therapeutics

Keywords

  • Angiogenesis
  • Anthrax toxin
  • ANTXR1/TEM8
  • ANTXR2/CMG2
  • Cell growth inhibition
  • Human xenograft
  • Lethal factor
  • Lethal toxin
  • Protective antigen
  • Receptor protein expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts : Assessment of receptor contribution. / Rouleau, Cecile; Menon, Krishna; Boutin, Paula; Guyre, Cheryl; Yoshida, Hitoshi; Kataoka, Shiro; Perricone, Michael; Shankara, Srinivas; Frankel, Arthur E.; Duesbery, Nicholas S.; Vande Woude, George; Biemann, Hans Peter; Teicher, Beverly A.

In: International Journal of Oncology, Vol. 32, No. 4, 04.2008, p. 739-748.

Research output: Contribution to journalArticle

Rouleau, C, Menon, K, Boutin, P, Guyre, C, Yoshida, H, Kataoka, S, Perricone, M, Shankara, S, Frankel, AE, Duesbery, NS, Vande Woude, G, Biemann, HP & Teicher, BA 2008, 'The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution', International Journal of Oncology, vol. 32, no. 4, pp. 739-748.
Rouleau, Cecile ; Menon, Krishna ; Boutin, Paula ; Guyre, Cheryl ; Yoshida, Hitoshi ; Kataoka, Shiro ; Perricone, Michael ; Shankara, Srinivas ; Frankel, Arthur E. ; Duesbery, Nicholas S. ; Vande Woude, George ; Biemann, Hans Peter ; Teicher, Beverly A. / The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts : Assessment of receptor contribution. In: International Journal of Oncology. 2008 ; Vol. 32, No. 4. pp. 739-748.
@article{451d9bcc97d14ad1a7d80b33187ee499,
title = "The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution",
abstract = "Two of the three components of anthrax toxin, protective antigen (PA) and lethal factor (LF), together known as lethal toxin (LeTx), reportedly show anti-tumor activity in melanoma in vitro and in vivo. The growth inhibitory activity of LeTx in culture was determined in nine human cancer cell lines, including melanoma, neuroblastoma and adenocarcinoma cells, as well as in human umbilical vein endothelial cells (HUVEC). The contribution of the two known PA receptor proteins, ANTXR1/TEM8 and ANTXR2/CMG2, to the sensitivity of the cells was assessed. The efficacy of LeTx was evaluated in vivo in the SK-N-AS neuroblastoma and SK-MEL-28 melanoma tumor xenograft models. Sensitivity to LeTx in vitro was observed in the neuroblastoma and colorectal adenocarcinoma cells and HUVEC, as well as melanoma cells. ANTXR1/TEM8 and ANTXR2/CMG2 protein expression studies suggested that a certain threshold of the PA receptor protein level must be met for sensitivity to LeTx to be observed. However, although the SK-N-AS neuroblastoma cells expressed the highest levels of receptor proteins and achieved the lowest IC50 in vitro (0.1 ng/ml), we observed no correlation between either the ANTXR1/TEM8 or ANTXR2/CMG2 protein levels and sensitivity to LeTx in vitro, In vivo, LeTx was an active anti-tumor agent when administered intravenously to mice bearing the human SK-N-AS or SK-MEL-28 tumor xenografts. The tumor growth delays were 6-8 days with a lower dose regimen and 14-16 days with a higher dose regimen for the two tumor models. These in vitro data suggest that LeTx may have broad therapeutic indications in cancer and the in vivo studies demonstrate that LeTx has systemic efficacy in neuroblastoma as well as melanoma. The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein.",
keywords = "Angiogenesis, Anthrax toxin, ANTXR1/TEM8, ANTXR2/CMG2, Cell growth inhibition, Human xenograft, Lethal factor, Lethal toxin, Protective antigen, Receptor protein expression",
author = "Cecile Rouleau and Krishna Menon and Paula Boutin and Cheryl Guyre and Hitoshi Yoshida and Shiro Kataoka and Michael Perricone and Srinivas Shankara and Frankel, {Arthur E.} and Duesbery, {Nicholas S.} and {Vande Woude}, George and Biemann, {Hans Peter} and Teicher, {Beverly A.}",
year = "2008",
month = "4",
language = "English (US)",
volume = "32",
pages = "739--748",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts

T2 - Assessment of receptor contribution

AU - Rouleau, Cecile

AU - Menon, Krishna

AU - Boutin, Paula

AU - Guyre, Cheryl

AU - Yoshida, Hitoshi

AU - Kataoka, Shiro

AU - Perricone, Michael

AU - Shankara, Srinivas

AU - Frankel, Arthur E.

AU - Duesbery, Nicholas S.

AU - Vande Woude, George

AU - Biemann, Hans Peter

AU - Teicher, Beverly A.

PY - 2008/4

Y1 - 2008/4

N2 - Two of the three components of anthrax toxin, protective antigen (PA) and lethal factor (LF), together known as lethal toxin (LeTx), reportedly show anti-tumor activity in melanoma in vitro and in vivo. The growth inhibitory activity of LeTx in culture was determined in nine human cancer cell lines, including melanoma, neuroblastoma and adenocarcinoma cells, as well as in human umbilical vein endothelial cells (HUVEC). The contribution of the two known PA receptor proteins, ANTXR1/TEM8 and ANTXR2/CMG2, to the sensitivity of the cells was assessed. The efficacy of LeTx was evaluated in vivo in the SK-N-AS neuroblastoma and SK-MEL-28 melanoma tumor xenograft models. Sensitivity to LeTx in vitro was observed in the neuroblastoma and colorectal adenocarcinoma cells and HUVEC, as well as melanoma cells. ANTXR1/TEM8 and ANTXR2/CMG2 protein expression studies suggested that a certain threshold of the PA receptor protein level must be met for sensitivity to LeTx to be observed. However, although the SK-N-AS neuroblastoma cells expressed the highest levels of receptor proteins and achieved the lowest IC50 in vitro (0.1 ng/ml), we observed no correlation between either the ANTXR1/TEM8 or ANTXR2/CMG2 protein levels and sensitivity to LeTx in vitro, In vivo, LeTx was an active anti-tumor agent when administered intravenously to mice bearing the human SK-N-AS or SK-MEL-28 tumor xenografts. The tumor growth delays were 6-8 days with a lower dose regimen and 14-16 days with a higher dose regimen for the two tumor models. These in vitro data suggest that LeTx may have broad therapeutic indications in cancer and the in vivo studies demonstrate that LeTx has systemic efficacy in neuroblastoma as well as melanoma. The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein.

AB - Two of the three components of anthrax toxin, protective antigen (PA) and lethal factor (LF), together known as lethal toxin (LeTx), reportedly show anti-tumor activity in melanoma in vitro and in vivo. The growth inhibitory activity of LeTx in culture was determined in nine human cancer cell lines, including melanoma, neuroblastoma and adenocarcinoma cells, as well as in human umbilical vein endothelial cells (HUVEC). The contribution of the two known PA receptor proteins, ANTXR1/TEM8 and ANTXR2/CMG2, to the sensitivity of the cells was assessed. The efficacy of LeTx was evaluated in vivo in the SK-N-AS neuroblastoma and SK-MEL-28 melanoma tumor xenograft models. Sensitivity to LeTx in vitro was observed in the neuroblastoma and colorectal adenocarcinoma cells and HUVEC, as well as melanoma cells. ANTXR1/TEM8 and ANTXR2/CMG2 protein expression studies suggested that a certain threshold of the PA receptor protein level must be met for sensitivity to LeTx to be observed. However, although the SK-N-AS neuroblastoma cells expressed the highest levels of receptor proteins and achieved the lowest IC50 in vitro (0.1 ng/ml), we observed no correlation between either the ANTXR1/TEM8 or ANTXR2/CMG2 protein levels and sensitivity to LeTx in vitro, In vivo, LeTx was an active anti-tumor agent when administered intravenously to mice bearing the human SK-N-AS or SK-MEL-28 tumor xenografts. The tumor growth delays were 6-8 days with a lower dose regimen and 14-16 days with a higher dose regimen for the two tumor models. These in vitro data suggest that LeTx may have broad therapeutic indications in cancer and the in vivo studies demonstrate that LeTx has systemic efficacy in neuroblastoma as well as melanoma. The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein.

KW - Angiogenesis

KW - Anthrax toxin

KW - ANTXR1/TEM8

KW - ANTXR2/CMG2

KW - Cell growth inhibition

KW - Human xenograft

KW - Lethal factor

KW - Lethal toxin

KW - Protective antigen

KW - Receptor protein expression

UR - http://www.scopus.com/inward/record.url?scp=44449130070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449130070&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 739

EP - 748

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -